ISRCTN70977225
Completed
Not Applicable
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorder
Institute of Psychiatry, Kings College London (UK)0 sites24 target enrollmentFebruary 5, 2009
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Obsessive-compulsive disorder
- Sponsor
- Institute of Psychiatry, Kings College London (UK)
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM\-IV) diagnosis of OCD
- •2\. Aged 12 to 18 years
- •3\. Either sex
- •4\. Any ethnicity, religious background or sexual orientation
- •5\. Referred to the National and Specialist OCD Clinic at Maudsley Hospital
- •6\. If on medication, this should be stable for 12 weeks and not be changed during the course of the trial
- •7\. Provision of written informed consent (patient and carer)
Exclusion Criteria
- •1\. Current diagnosis of psychosis, current alcohol or substance abuse/dependence
- •2\. English too poor to engage in treatment
- •3\. Severe disabling neurological disorder
- •4\. Medical contraindication to cycloserine, including epilepsy and porphyria
- •5\. A diagnosed global learning disability or pervasive developmental disorder
- •6\. Characteristics interfering with completion of treatment, e.g. life threatening or unstable medical illness
- •7\. Pregnancy
- •8\. Not suitable for CBT (selective mutism, lack of insight or motivation for change)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A randomised double-blind placebo-controlled pilot study of D-cycloserine-augmented exposure therapy in adolescents with obsessive-compulsive disorderEUCTR2008-006947-38-GBKing's College London (Institute of Pyschiatry)24
Active, not recruiting
Phase 1
Trial of oxytocin for the treatment of emotional withdrawal symptoms and for relapse prevention in abstinent heroin dependent individualsOpioid dependence. The study will be investigating the efficacy of Syntocinon (oxytocin) on treating the withdrawal symptoms and cravings that opioid (e.g. almost always heroin) dependent individuals experience following detoxification.MedDRA version: 20.0 Level: LLT Classification code 10057379 Term: Addiction relapse System Organ Class: 100000004873MedDRA version: 20.0 Level: LLT Classification code 10001126 Term: Addiction any drug System Organ Class: 100000004873Therapeutic area: Psychiatry and Psychology [F] - Mental Disorders [F03]EUCTR2014-002708-26-GBniversity of Surrey3
Recruiting
Not Applicable
Immunoglobulin therapy in Lung TransplantTransplantationRespiratory - Other respiratory disorders / diseasesACTRN12618001394235The Alfred Hospital40
Completed
Not Applicable
A randomised, double-blinded clinical study of LC for systemic lupus erythematosus patientsSystemic lupus erythematosus (SLE)Musculoskeletal DiseasesISRCTN81818883Department of Health (Taiwan) - Executive Yuan90
Not yet recruiting
Phase 3
The Myer Foundation Study into Multiple SclerosisRelapsing remitting multiple sclerosisNeurological - Multiple sclerosisACTRN12606000359538Melbourne Health20